Good evening :)
Place Order
Add to Watchlist

Vimta Labs Ltd

VIMTALABS

Vimta Labs Ltd

VIMTALABS
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹2,008 cr, stock is ranked 1,147
High RiskStock is 3.53x as volatile as Nifty
923.851.69% (+15.35)
923.851.69% (+15.35)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹2,008 cr, stock is ranked 1,147
High RiskStock is 3.53x as volatile as Nifty

How to use scorecard? Learn more

Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹2,008 cr, stock is ranked 1,147
High RiskStock is 3.53x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
40.166.280.22%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.116.510.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Vimta Labs Limited is engaged in providing testing and contract research services in the fields of clinical and pre-clinical studies, clinical reference, analytical testing, advanced molecular biology and environmental studies.

Investor Presentation

View older 

Nov 8, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue183.73211.51279.73321.63322.27323.75
Raw Materialssubtract32.4135.2554.8144.1348.69222.29
Power & Fuel Costsubtract0.000.000.000.000.00
Employee Costsubtract57.6357.8071.4286.3295.30
Selling & Administrative Expensessubtract26.5021.7328.5643.2338.83
Operating & Other expensessubtract34.2242.9444.4349.6048.65
Depreciation/Amortizationsubtract20.9323.0823.3330.7134.2033.05
Interest & Other Itemssubtract3.772.171.502.652.121.95
Taxes & Other Itemssubtract1.427.1414.3616.8313.4716.45
EPS3.109.6818.6921.7718.5122.56
DPS0.002.002.002.002.002.00
Payout ratio0.000.210.110.090.110.09

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2023

Annual report

PDF

Investor Presentation

May 3PDF
FY 2024

Annual report

PDF

Investor Presentation

Jul 28PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 8PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Vimta Labs Ltd48.976.280.22%
Divi's Laboratories Ltd102.4212.070.49%
Syngene International Ltd74.018.860.13%
Aarti Pharmalabs Ltd26.493.270.47%

Price Comparison

Compare VIMTALABS with any stock or ETF
Compare VIMTALABS with any stock or ETF
VIMTALABS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 2.89%

Decreased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 1.85%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding36.89%0.00%0.00%3.31%59.80%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep2.72%2.74%2.88%5.13%5.16%3.31%

Mutual Funds Holding Trend

Decreased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.49%

Top 2 Mutual Funds holding Vimta Labs Ltd



Funds (Top 2)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0003%0.03%0.03%97/102 (-2)
Quant Small Cap Fund - Growth - Direct Plan

Growth
0.0000%0.00%-0.07%32/94 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 11, 2024

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jul 11, 2024

Cash Dividend

Ex DateEx DateJun 21, 2023

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jun 21, 2023

Cash Dividend

Ex DateEx DateJun 16, 2022

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jun 16, 2022

Cash Dividend

Ex DateEx DateJun 25, 2021

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jun 25, 2021

Cash Dividend

Ex DateEx DateJul 18, 2019

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jul 18, 2019

News & Opinions
Earnings
Vimta Labs consolidated net profit rises 140.92% in the September 2024 quarter

Net profit of Vimta Labs rose 140.92% to Rs 15.25 crore in the quarter ended September 2024 as against Rs 6.33 crore during the previous quarter ended September 2023. Sales rose 29.30% to Rs 84.74 crore in the quarter ended September 2024 as against Rs 65.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales84.7465.54 29 OPM %35.3026.56 - PBDT30.1818.84 60 PBT21.8910.19 115 NP15.256.33 141 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Vimta Labs to hold board meeting

Vimta Labs will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Vimta Labs completes sale of its diagnostic and pathological services business

Vimta Labs has completed the sale and transfer of its diagnostic and pathological services business as a going concern to Thyrocare Technologies on 11 October 2024. Powered by Capital Market - Live

1 month agoCapital Market - Live

Vimta Labs consolidated net profit rises 0.66% in the June 2024 quarter

4 months agoBusiness Standard

Vimta Labs Consolidated March 2023 Net Sales at Rs 81.82 crore, up 10.44% Y-o-Y

1 year agoMoneycontrol

Stocks to watch on May 3, 2023

1 year agoThe Hindu Businessline

Heranba Industries Ltd leads losers in ‘B’ group

1 year agoBusiness Standard

Vimta Labs Consolidated December 2022 Net Sales at Rs 77.38 crore, up 14.92% Y-o-Y

1 year agoMoneycontrol

Vimta Labs consolidated net profit rises 35.63% in the September 2022 quarter

2 years agoBusiness Standard

VIMTA Labs forays into electrical, electronics testing

2 years agoThe Hindu Businessline